Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

EMPACTA, 2020
 
NCT04372186
RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
259/129 conclusif
  • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID-19 severe or criticallylow
161/81 inconclusive
  • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
294/144 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).